|
|
|
|
|
February 9-10, 2010
Meeting Summary
|
Table of Contents
|
I. Record of Attendance
|
II. Clinical Laboratory Improvement Advisory Committee (CLIAC)
- Background
|
III. Call to Order and Committee Introductions
|
IV. Agency Updates and Committee Discussion
|
V. Presentations and Committee Discussion
- Good Laboratory Practices for Biochemical Genetic Testing Workgroup Report
- Electronic Health Records and CLIA
- Electronic Transmission of Laboratory Information and Oversight of Laboratory Information
Systems
|
VI. Public Comments
|
VII. Adjourn
|
VIII. Addenda
|
Record of Attendance
|
|
Committee Members Present
|
Ms. Elissa Passiment, Chair
|
|
Dr. James Nichols
|
Dr. Judy Daly
|
|
Dr. Stephen Raab
|
Dr. Nancy Elder
|
|
Dr. Linda Sandhaus
|
Dr. John Fontanesi
|
|
Dr. Paula Santrach
|
Ms. Julie Gayken
|
|
Dr. Gail Vance
|
Dr. Geraldine Hall
|
|
Dr. Emily Winn-Deen
|
Dr. Norman Harbaugh, Jr.
|
|
Dr. Rosemary Zuna
|
Dr. Paul Kimsey
|
|
|
Ms. Luann Ochs, AdvaMed (Liaison Representative)
|
|
|
Committee Members Absent
|
Dr. Ellen Jo Baron
|
Dr. Gary Overturf
|
Dr. Christine Bean
|
Ms. Susan Cohen
|
|
|
Executive Secretary
|
|
|
Ex Officio Members
|
Dr. Alberto Gutierrez, FDA
|
Dr. Roberta Carey, CDC
|
Ms. Judith Yost, CMS
|
|
|
|
Centers for Disease Control and Prevention
|
Mr. Todd Alspach
|
|
Ms. Jan Nicholson
|
Ms. Nancy Anderson
|
|
Mr. Richard Olney
|
Dr. Rex Astles
|
|
Ms. Abrienne Patta
|
Ms. Inger Baker
|
|
Ms. Anne Pollock
|
Ms. Diane Bosse
|
|
Ms. Angela Ragin-Wilson
|
Dr. Bin Chen
|
|
Ms. Cheri Rice
|
Dr. Carlyn Collins
|
|
Dr. Shahram Shahangian
|
Ms. Joanne Eissler
|
|
Mr. Darshan Singh
|
Ms. MariBeth Gagnon
|
|
Ms. Theresia Snelling
|
Dr. Genny Barkog Gallagher
|
|
Dr. Susan Snyder
|
Dr. James Handsfield
|
|
Ms. Heather Stang
|
Ms. Pat Haskell
|
|
Ms. Cynthia Sturchio
|
Dr. Lisa Kalman
|
|
Dr. Shambavi Subbarao
|
Dr. Joan Knapp
|
|
Dr. Julie Taylor
|
Ms. Debra Kuehl
|
|
Mr. Howard Thompson
|
Dr. Ira Lubin
|
|
Ms. Pamela Thompson
|
Ms. Leslie McDonald
|
|
Ms. Irene Willaims
|
Dr. Joanne Mei
|
|
Dr. Barbara Zehnbauer
|
Ms. Andrea Murphy
|
|
|
|
|
Department of Health and Human Services (Agencies other than CDC)
|
Ms. Carol Benson (FDA)
|
|
Mr. Jonathan Ishee (ONC-HHS)
|
Mr. Michael Brophy (VA)
|
|
Ms. Penelope Meyers (CMS)
|
Ms. Minnie Christian (CMS)
|
|
Mr. Charles Reynolds (CMS)
|
Dr. Elliot Cowan (FDA)
|
|
Ms. Ann Snyder (CMS)
|
Ms. Karen Dyer (CMS)
|
|
Ms. Kathleen Todd (CMS)
|
Ms. Daralyn Hassan (CMS)
|
|
Ms. Harriet Walsh (CMS)
|
|
|
In accordance with the provisions of Public Law 92-463, the meeting was open to
the public. Approximately 30 public citizens attended one or both days of the meeting.
|
|
Clinical Laboratory Improvement Advisory Committee
|
The Secretary of Health and Human Services is authorized under Section 353 of the
Public Health Service Act, as amended, to establish standards to assure consistent,
accurate, and reliable test results by all clinical laboratories in the United States.
The Secretary is authorized under Section 222 to establish advisory Committees.
The Clinical Laboratory Improvement Advisory Committee (CLIAC) was chartered in
February 1992 to provide scientific and technical advice and guidance to the Secretary
and the Assistant Secretary for Health regarding the need for, and the nature of,
revisions to the standards under which clinical laboratories are regulated; the
impact on medical and laboratory practice of proposed revisions to the standards;
and the modification of the standards to accommodate technological advances.
The Committee consists of 20 members, including the Chair. Members are selected
by the Secretary from authorities knowledgeable in the fields of microbiology, immunology,
chemistry, hematology, pathology, and representatives of medical technology, public
health, clinical practice, and consumers. In addition, CLIAC includes three ex officio
members, or designees: the Director, Centers for Disease Control and Prevention;
the Commissioner, Food and Drug Administration; the Administrator, Centers for Medicare
& Medicaid Services; and such additional officers of the U.S. Government that the
Secretary deems are necessary for the Committee to effectively carry out its functions.
CLIAC also includes a non-voting liaison representative who is a member of AdvaMed
and such other non-voting liaison representatives that the Secretary deems are necessary
for the Committee to effectively carry out its functions. Due to the diversity of
its membership, CLIAC is at times divided in the guidance and advice it offers to
the Secretary. Even when all CLIAC members agree on a specific recommendation, the
Secretary may not follow their advice due to other overriding concerns. Thus, while
some of the actions recommended by CLIAC may eventually result in changes to the
regulations, the reader should not infer that all of the Committee’s recommendations
will be automatically accepted and acted upon by the Secretary.
|
CALL TO ORDER AND COMMITTEE INTRODUCTIONS
|
Dr. Thomas Hearn, Designated Federal Official, CLIAC, Acting Director, National
Center for Emerging and Zoonotic Infectious Diseases (NCEZID) (Proposed), CDC, welcomed
the Committee and the members of the public, acknowledging the importance of public
participation in the advisory process. He explained the meeting would focus on three
main topics: "Good Laboratory Practices for Biochemical Genetic Testing;" "Electronic
Health Records (EHRs) and CLIA;" and "Electronic Transmission of Laboratory Information
and Oversight of Laboratory Information Systems."
Focus would be placed on the Biochemical Genetic Testing Workgroup’s report in order
for CLIAC to provide recommendations to the Department of Health and Human Services
(HHS) for good laboratory practices for genetic testing. These recommendations are
intended to be published in a Morbidity and Mortality Weekly Report Recommendations
and Reports (MMWR R&R). With respect to the other topics, an overview of the progress
that the Office of the National Coordinator for Health Information Technology has
made towards implementation of Electronic Health Records, implications of EHRs in
the context of CLIA regulations, and the FDA’s classification of and the regulations
that apply to laboratory information systems will be discussed.
|
|
Board of Scientific Counselors - Update
|
Addendum A
|
Ms. Elissa Passiment, Chair, CLIAC
Executive Vice President
American Society for Clinical Laboratory Science
Ms. Passiment reported on the November 2009 meeting of the Board of Scientific Counselors
(BSC), a federal advisory committee that serves the CDC infectious disease centers
and meets to discuss high priority infectious disease issues. The two day agenda
included an overview of CDC’s environmental microbiology activities; a review of
the American Recovery and Reinvestment Act (ARRA) funding for immunization programs;
updates on the peer reviews for programs within two infectious disease centers;
an update on CDC’s organizational changes and priorities by Dr. Rima Khabbaz, the
acting Deputy Director of Infectious Diseases at CDC, Dr. Steve Blount, the acting
Director of the Center for Global Health, and Director of CDC, Dr. Thomas Frieden;
and a report on CDC’s activities in the investigation of influenza H1N1.
Ms. Passiment provided a summary of the environmental microbiology workgroup activities,
which included describing how the physical structure of healthcare facilities may
affect the rate of healthcare acquired infections. She related that CDC’s scientists
have interests in carrying out research in aerobiology (the study of the dispersion
of airborne biological materials such as pollen, spores, microorganisms, or viruses);
however, as CDC facilities may not be able to support the research, alternative
sites such as Fort Detrick are being considered. The BSC recommended that the environmental
microbiology workgroup coordinate its activities with the Environmental Protection
Agency, the Department of Homeland Security, and CDC’s infection control and epidemiology
groups. Ms. Passiment said the BSC suggested the environmental microbiology workgroup
be more proactive with regards to communication and education across all disciplines.
The H1N1 report covered testing, response, laboratory communications, the factors
surrounding the susceptibility of children to the disease, and how deaths relate
to pregnancy and obesity. CDC is in the process of analyzing data collected to determine
the actual impact of H1N1disease in the U.S. Ms. Passiment concluded the presentation
by noting the need for more public relations in the “regular community” regarding
vaccination.
|
|
AGENCY UPDATES AND COMMITTEE DISCUSSION
|
|
Food and Drug Administration (FDA) Update
|
Addenda B
|
Alberto Gutierrez, Ph.D.
Director, Office of In-Vitro Diagnostic Device Evaluation and Safety (OIVD)
Center for Devices and Radiological Health (CDRH)
Food and Drug Administration
Dr. Gutierrez listed recent FDA staffing changes, notably Dr. Jeff Shuren as Director
of the CDRH. He reported on agency initiatives, including efforts to pro-actively
manage public health issues such as use of glucose meters in healthcare settings,
the implementation of personalized medicine, and responding to emerging infectious
diseases. He also described FDA’s attempts to ensure transparency of their actions
and processes using communication outlets like Twitter, YouTube, and public meetings.
Dr. Gutierrez explained at the Center level, the 510(k) program will be undergoing
internal and Institute of Medicine reviews allowing outside entities an opportunity
to provide feedback. He reviewed recently published FDA guidances for antimicrobial
susceptibility tests, part of a joint effort between OIVD and the Center for Drug
Evaluation and Research concerning labeling; detection or detection and differentiation
of HPV; several special controls guidances; and H1N1 Emergency Use Authorizations
(EUA) for both manufacturers and laboratories. Dr. Gutierrez commented on one notable
new clearance, OVA1, used for the detection of ovarian cancer. He also noted 14
EUAs for influenza H1N1 will expire in April 2010 unless reauthorized by the Secretary
of HHS. He detailed agency postmarket actions which included Class I recalls, public
health notifications, and warning letters. Dr. Gutierrez concluded his presentation
by briefly reviewing CLIA waivers, including a summary of tests waived by FDA, as
well as examples of the FDA timeframes for waiver reviews.
|
|
|
Centers for Medicare and Medicaid Services (CMS) Update
Judith Yost, M.A., MT (ASCP)
Director, Division of Laboratory Services
Center for Medicaid and State Operations
Centers for Medicaid & Medicaid Services
|
Addendum C
Addendum D
Addendum E
Addendum F
Addendum G
Addendum H
|
Ms. Yost began her presentation with an overview of current CLIA statistics showing
a large percentage of the laboratories perform 10,000 tests per year or less and
that the number of waived laboratories continues to increase. She reported on the
progress of the cytology proficiency testing (PT) proposed regulation, stating suggestions
and comments are being analyzed. Next, she reviewed CMS’s most cited deficiencies
and enforcement data. Ms. Yost then updated the Committee on alternative quality
control (QC) development including the collaboration between CMS and the Clinical
and Laboratory Standards Institute (CLSI). She said the new alternative QC will
be phased in by CMS and the interpretive guidelines will be revised. She also reported
on the CMS plan to update all aspects of the PT regulations. Ms. Yost said a CLIAC
PT workgroup meeting is scheduled for March 2010, and the workgroup report will
be presented to CLIAC at the next meeting in September 2010. Ms. Yost presented
statistics on certificate of waiver (CW) laboratory performance including voluntary
PT and detailed the next steps towards efforts to improve the quality of waived
testing. She listed CMS’ short term goals which include continuing the CW project
indefinitely, soliciting data from accrediting organizations and other sources that
have CW standards, and coordinating with the FDA to address overlapping issues.
Finally, she stated the ideal long term goal would be to improve the level of oversight
of sites that perform waived testing by changing the CLIA law. Ms. Yost summarized
the CLIA requirements and issues pertaining to EHRs and said new CMS guidance pertaining
to EHRs is forthcoming. She also noted a new brochure that provides simple mechanisms
to file a complaint has been developed and is accessible on the CLIA website. The
brochure will be distributed to all laboratories over the next two years. Ms. Yost
concluded her presentation with a review of CLIA personnel requirements and inspection
policies, focusing on personnel qualifications and the ramifications that could
occur if the requirements are not being met.
Committee Discussion
- One member voiced support for getting feedback from accrediting and professional
organizations regarding waived testing. Inspecting waived testing sites could have
the potential to improve test quality, but physicians may view inspections as an
imposition in terms of time, money, and aggravation. Ms. Yost noted that a certain
percentage of waived laboratories or other sites that only perform waived testing
receive educational visits from CMS. CMS is exploring the possibility of minimal
periodic oversight, although not to the extent of non-waived laboratory inspections.
The same member replied voluntary oversight will not be accepted. Ms. Yost responded
CMS would like to see the CLIA law minimally changed thereby giving CMS some oversight
discretion. The agency would appreciate insight and suggestions from professional
organizations and is seeking a constructive approach.
- Another member inquired whether CMS or the accrediting organizations have a list
of certified laboratories. Ms. Yost referred the member to the “Laboratory Demographics
Lookup” tool on the CMS CLIA website. If additional information is required, Ms.
Yost suggested contacting the relevant state agency.
- One member asked what the ramifications are if a laboratory does not follow the
manufacturer’s instructions for a waived test or engages in off-label use of the
test i.e., in a different clinical setting for uses not specified in the manufacturer’s
instructions. Ms. Yost responded a laboratory’s waiver certificate can be removed
if manufacturer’s instructions are not being followed, especially if there is immediate
jeopardy to the patient. If a waived test is performed outside of its intended use,
it defaults to a high complexity test, and the laboratory must meet the standards
for high complexity testing or stop using the test. Dr. Gutierrez added this is
a complex and challenging issue. He cited, as an example, waived devices or tests
that measure hemoglobin A1c. The American Diabetes Association has put forth new
recommendations to allow diagnosis of diabetes based on hemoglobin A1c results.
Since the intended use of waived tests for hemoglobin A1c does not include diagnosis
of diabetes, their use for this purpose would be outside of the intended use and
considered off-label. Dr. Gutierrez stated as medicine and technology change, similar
issues will continue to arise.
|
|
Centers for Disease Control and Prevention (CDC) Update
|
Addendum I
|
Roberta B. Carey, Ph. D.
Acting Director, Division of Laboratory Systems
National Center for Emerging and Zoonotic Infectious Diseases (proposed)
Division of Laboratory Systems
Centers for Disease Control and Prevention
Dr. Carey presented an overview of the reorganization taking place at CDC, noting
the Division of Laboratory System’s move to the Office of Surveillance, Epidemiology,
and Laboratory Services headed by Dr. Stephen Thacker. She described the CLIAC Proficiency
Testing Workgroup’s charge and topics to be addressed at the March 2010 meeting.
Dr. Carey reported two cytology cooperative agreements were funded in 2010-2011
to the College of American Pathologists and Michigan Public Health Institute to
gather information on cytology laboratory testing and reporting practices. She summarized
the post-publication activities of the MMWR R&R article titled "Good
Laboratory Practices for Molecular Genetic testing for Heritable Diseases and Conditions."
Dr. Carey reviewed the goal and status of CDC’s Laboratory Medicine Best practices
project. She stated three pilot test topics and seven practices have been reviewed,
four of which had sufficient evidence to recommend as best practices. As a result
of the success of this project, several products are in preparation, including manuscripts,
presentations, a technical guide, and a web-based tutorial to educate laboratory
scientists regarding evidence-based reviews. Also, in the area of evidence-based
laboratory medicine, DLS has been examining quality/performance measures and Dr.
Carey discussed three ongoing initiatives as well as the progress and future plans
for this activity.
Next, Dr. Carey described an interactive training module, "Genetic Testing in Clinical
Practice: A Team Approach," a case-based interactive module designed for clinicians
or students to work their way through a simulated clinic to learn about the use
of genetic tests in medical practice. She outlined the Genetic Testing Reference
Material Program, which seeks to improve the availability of reference materials
for genetic testing. She described the goals and findings of the Rapid Influenza
Testing Survey, performed under a cooperative agreement with The Joint Commission,
and said a second survey is to be conducted later this year. Dr. Carey concluded
her presentation by giving status reports on the Laboratory Medicine Roadmap and
the Laboratory Medicine Integrations Workgroups.
Committee Discussion
- One member asked Dr. Carey if she anticipated any interagency work in the area
of best practices with the Agency for Healthcare Research and Quality (AHRQ). Dr.
Carey responded that AHRQ would be a natural partner, but their focus is not on
the laboratory.
|
|
PRESENTATIONS AND COMMITTEE DISCUSSIONS
|
Introduction: CLIAC Biochemical Genetic Testing Workgroup
– Good Laboratory Practices for Biochemical Genetic Testing and Newborn Screening
for Heritable Diseases
|
Addenda J and
K
|
Bin Chen, Ph.D., FACMG
Laboratory Research and Evaluation Branch (Proposed)
Division of Laboratory Science and Regulation (Proposed)
Laboratory Science, Policy and Practice Program Office (Proposed)
Office of Surveillance, Epidemiology and Laboratory Services (Proposed)
Centers for Disease Control and Prevention
Dr. Chen presented the introduction for the CLIAC Biochemical Genetic Testing Workgroup.
She provided background information on the current oversight for biochemical genetic
testing (BGT) derived from the CLIA regulations, the FDA requirements for in vitro
diagnostic devices, state requirements, voluntary professional practice guidelines,
and accreditation requirements. She reviewed the CLIAC activities related to BGT
since 2007, including the recommendation in September 2008 to form a workgroup on
BGT for good laboratory practices (GLP). Dr. Chen addressed the CDC assessment of
the BGT landscape and quality assurance (QA) gaps including issues for workgroup
consideration, areas of expertise needed for the workgroup, and information needed
to facilitate the workgroup’s evaluation of current standards. One example of an
issue needing the workgroup’s input was the determination of which tests the prospective
good laboratory practice recommendations should apply. Dr. Chen explained that existing
definitions for BGT vary depending on the context and purpose of testing; although
CLIAC recommended a definition “analysis of human gene products, metabolites to
detect inborn errors of metabolism (IEM), heritable genotypes or disorders,” most
BGT laboratories are currently self-designated. On the other hand, most of the diseases
screened for by state newborn screening (NBS) programs are IEM and the presumptive
positive NBS cases need to be confirmed with diagnostic testing such as specialized
biochemical genetic tests. She also addressed the lack of up-to-date, comprehensive
data for test volume and the number of BGT laboratories. Dr. Chen stated that, in
preparation for the BGT Workgroup deliberations, CDC prepared 19 comprehensive crosswalks
and identified additional issues to be resolved. CDC anticipates publication of
an MMWR R&R in 2011 that will incorporate CLIAC’s recommendations for
GLPs for BGT.
|
|
Good Laboratory Practices for Biochemical Genetic Testing
and Newborn Screening for Heritable Diseases
|
Addenda L and
M
|
Carol Greene, M.D., FACMG
Director, Clinical Genetics and Metabolism Service
Department of Pediatrics
University of Maryland School of Medicine
Dr. Greene, Chair, CLIAC BGT Workgroup, introduced the workgroup members and ex
officio participants whose primary charge was to provide input to CLIAC leading
to the development of recommendations for GLPs for BGT. She said the workgroup reviewed
the 19 comprehensive crosswalks prepared by CDC and used them as the starting point
for their discussions about each of the eight BGT key areas. The workgroup report
provided suggestions and clarifications on the scope and applicability, total testing
process (i.e., preanalytic, analytic, postanalytic phases), PT and alternative assessments,
confidentiality, personnel qualifications and responsibilities, considerations before
introducing genetic testing or offering new BGTs, and quality management systems
(QMS).
Ms. Passiment and the Committee commended Dr. Greene and the workgroup members for
their efforts to provide a comprehensive list of suggestions for GLPs for BGTs.
The Chair directed Committee members to discuss each aspect of the workgroup report.
The Committee recommended adopting the document with the following additions or
modifications.
|
|
CLIAC Additions or Modifications to BGT Workgroup Suggestions
|
Addendum O
|
Scope and Applicability:
- One member commented that many non-geneticists do not understand BGT and a geneticist
should be consulted, when needed, for ordering or interpretation of tests. Dr. Greene
responded that this comment pertains to physician education and clarified that the
document covers GLPs for the laboratory performing the test but encourages physicians
to consult with geneticists.
- There was discussion about which tests were considered biochemical genetic tests.
A member said there is crossover between biochemical testing for other purposes
and BGT, making it difficult to determine which tests to include in BGT. Therefore,
the BGT GLPs could be applied to most testing performed in biochemical genetic laboratories
but not to all. Dr. Greene agreed and stated the workgroup also included tests for
the diagnosis and monitoring of IEM which include NBS and rare genetic testing performed
by a biochemical genetic testing laboratory.
- A member suggested simplifying the document by focusing on the preanalytic and
postanalytic phases of testing where BGT differs from other laboratory testing.
Dr. Greene replied the intent of the workgroup deliberations and report was to provide
guidance for CLIAC to consider on GLPs for laboratories that want to start performing
BGT, laboratories that want to add new biochemical genetic tests to their menus,
and for use as comprehensive guidance for any laboratories that perform BGT.
- A member suggested the title of the summary of CLIAC recommendations be changed
to "Biochemical Genetic Testing and Newborn Screening for Diagnosis and Monitoring
of Inborn Errors of Metabolism" or "Good Laboratory Practice for Diagnosis and Monitoring
of Inborn Errors of Metabolism using Biochemical Genetic Testing and Newborn Screening"
to address the clinical aspect of testing.
- One member suggested the MMWR R&R introduction needs to stress that
much of the information on GLPs applies to all laboratory testing, with BGT differing
in the preanalytic and postanalytic phases of testing.
Preanalytic Phase:
Information to be Provided to Users of Laboratory Services
- One member inquired about pre-authorization for BGT, noting it was included in
the MMWR R&R for molecular genetic testing. The workgroup agreed pre-authorization
should be part of any published GLP guidelines.
Informed Consent
- For the topic of informed consent, one member suggested separating NBS from other
BGT. Dr. Greene suggested that a clarification of the differences be addressed in
the MMWR R&R publication. Dr. Chen added that CDC subject matter experts
and BGT workgroup experts on NBS were consulted and had determined that most of
the key points applied to both NBS and other BGT, so there was no need to separate
them. However, the MMWR R&R document will offer a more user-friendly
explanation of the differences in informed consent.
- Dr. Gutierrez suggested the workgroup consult with the Secretary’s Advisory Committee
for Genetics, Health, and Society (SACGHS) and the Advisory Committee for Heritable
Diseases in Newborns and Children (ACHDNC), which is also considering best practices
for informed consent and sample retention in NBS, to ensure agreement on recommended
GLPs. Dr. Greene informed CLIAC that the workgroup was provided with documents from
SACGHS and ACHDNC to use for reference. Updates will be provided to both SACGHS
and ACHDNC regarding CLIAC recommendations for BGT and NBS.
Test Request
- No additions or clarifications.
Specimen Submission, Handling, and Referral
- The Chair suggested clarification of the terminology on inadequate specimens and
how these specimens would still meet the laboratory’s acceptance criteria for testing.
Dr. Greene clarified that in certain BGT laboratories the entire specimen is judged
as adequate or inadequate for all testing to be done, so the specimen would be reported
as inadequate if it was inadequate for any test in the panel even though it was
adequate for a specific test. The Chair commented such specimens, therefore, should
not be reported as inadequate for all tests requested, but just for those tests
for which the specimen is truly unacceptable, and re-iterated the need for clarity
in CLIAC recommendations and a subsequent MMWR R&R.
- The Chair also commented that if a laboratory accepts a suboptimal or non-ideal
specimen, such as a hemolyzed specimen, it should have documentation of studies
to prove that the test to be performed and performance specifications will not be
compromised.
- Several CLIAC members said specimens for patient testing referral must be referred
to a CLIA-certified laboratory or a laboratory meeting equivalent requirements as
determined by CMS. They suggested the removal of language in any CLIAC recommendation
addressing referral of specimens to foreign non-CLIA certified laboratories.
- Ms. Yost commented that CMS has been exploring strategies for oversight of non-CLIA-certified
foreign laboratories that perform patient testing for U.S. patient specimens. Determining
equivalency has been a challenge due to the numerous different policies in countries
outside of the U.S.
- One member commented that the Collaboration Education and Test Translation Program
in The Office of Rare Diseases Research at the National Institutes of Health (NIH)
facilitates the translation of genetic tests from the research setting to CLIA-certified
laboratories through collaborations among clinicians, laboratories, researchers,
and disease-specific advocacy groups.
- CLIAC recognized that some rare biochemical genetic tests are needed for patient
care, but are not currently offered in CLIA-certified laboratories. The Committee
recommended that CMS and the Office of Rare Diseases Research at NIH identify specific
test gaps that exist today and seek support from the Office of Rare Diseases Research
to set up these tests in CLIA-certified laboratories. Support could include assisting
laboratories which currently offer these tests to obtain CLIA certification or offering
assistance in setting up these tests in existing CLIA laboratories.
Preanalytic Systems Assessment
- No additions or clarifications.
Analytic Phase:
Performance Establishment and Verification
- One member commented on establishing performance for a diagnostic test or specimen
type when sufficient numbers of normal and positive controls are not available.
Another member suggested including a reference for performance establishment or
verification requirements of low volume or rare tests. Dr. Greene commented SACGHS
and other groups have tried to address this issue and provide guidance but have
not been successful in coming up with a numerical requirement for establishing or
verifying performance for tests when specimens are not readily available.
- The Chair commented that it is not acceptable for a laboratory to test a specimen
and report results if they have not established or verified performance for that
specimen type using their test system. Even if this specimen is the only one available
for testing, accurate results cannot be assured.
Test Systems, Equipment, Instruments, Reagents, Materials, and Supplies
- No additions or clarifications.
Calibration and Calibration Verification Procedures
- No additions or clarifications.
Control Procedures
- No additions or clarifications.
Proficiency Testing (PT) and Alternative Performance Assessment
- Dr. Greene commented PT for BGT is often complicated due to lack of certain specimen
matrices such as spinal fluid and muscle biopsies. She stressed the importance of
alternative PT assessments in BGT.
Postanalytic Phase:
Test Report
- No additions or clarifications.
Retention of Records and Reports
- One member inquired whether the workgroup’s suggested 21 year retention of records
was for all documents associated with testing or just the test report. Dr. Greene
clarified that the test report should be retained for 21 years and other documents
retained as required by CLIA. She commented that for rare conditions, the workgroup
suggested retaining some records, such as QC and PT, for a longer period of time
to be used for educational purposes.
- One member asked why the workgroup proposed a 21 year record retention time for
BGT when 25 years was recommended for molecular genetic testing. Dr. Greene responded
that currently 21 years is the maximum amount of time an NBS testing facility will
retain documents. The workgroup has no objections to changing 21 years to 25 years
to maintain consistency with the molecular genetic testing guidelines.
Retention of Specimens
- One member suggested changing the wording from "low volume tests" to "low frequency
tests" when addressing the retention of specimens until the next PT event or external
quality assessment.
Postanalytic Systems Assessment and Other Issues
- No additions or clarifications.
Confidentiality
- No additions or clarifications.
Personnel Qualifications and Responsibilities:
Laboratory Director Qualifications and Responsibilities
- No additions or clarifications.
Technical Supervisor Qualifications and Responsibilities
- No additions or clarifications.
Clinical Consultant Qualifications and Responsibilities
- No additions or clarifications.
General Supervisor Qualifications and Responsibilities
- No additions or clarifications.
Testing Personnel Qualifications and Responsibilities
- No additions or clarifications.
Personnel Competency Assessment
- No additions or clarifications.
Additional Issues:
Considerations before Introducing Genetic Testing or Offering New Biochemical Genetic
Tests
- Dr. Greene stressed the focus should be patient care when considering the introduction
of low volume tests.
- Dr. Chen commented ACHDNC operates a systematic evidence-based review process to
determine which disorders will be recommended for inclusion into newborn screening
test panels nationwide. The workgroup encourages ACHDNC to consider the availability
of confirmatory tests in CLIA-certified laboratories before the introduction of
a new screening test.
Quality Management System (QMS) for Biochemical Genetic Testing
- One member suggested principles of quality assessment and quality management should
be stressed throughout the document.
|
|
Introduction: Electronic Health Records and Electronic Transmission
of Lab Information
|
Addendum P
|
Judith Yost, M.A., MT (ASCP)
Director, Division of Laboratory Services
Center for Medicaid and State Operations
Centers for Medicare & Medicaid Services
Ms. Yost introduced the topic of Health Information Technology (HIT) and EHRs providing
some background on the subject. Under Title 4 of the American Recovery and Reinvestment
Act ARRA, an incentive program was established for physicians who adopt, implement,
or use HIT. The HIT Committee in the Office of the National Coordinator for Health
Information Technology (ONC) (http://healthit.hhs.gov)
was established and reports to the Secretary of HHS. Together, the HIT Committee,
CMS, and the Office of E-Health Standards and Services have been working on the
issues that currently hinder electronic transmission of laboratory information.
|
|
Issues Surrounding the Electronic Exchange of Laboratory
Data
|
Addendum Q
|
Jonathan Ishee, JD, MPH, MS, LLM
Office of the National Coordinator for Health Information Technology
Mr. Ishee provided an update on the progress that the ONC has made pertaining to
EHR. Under the ARRA, an incentive program was established for the meaningful use
of certified EHR technology by eligible professionals. As a result, CMS was charged
with writing a Notice of Proposed Rulemaking (NPRM) on the incentive program’s meaningful
use of certified EHR technology by eligible professionals and ONC was charged with
writing an Interim Final Rule (IFR) on standards and certification criteria. The
ONC supported a study on state laws concerning persons authorized to order tests
and receive results and found 23 states did not identify who could be considered
an authorized person while others were prescriptive in their definition of an "authorized
person," with no uniform standard applied by all states. On October 20th, 2009,
a hearing was convened with EHR stakeholders to discuss issues surrounding the electronic
exchange of laboratory data. During the hearing, impediments to this exchange of
information were identified that fell into three major categories: standards/technological,
business, and perceived regulatory impediments. After the October hearing, CMS developed
a Survey and Certification letter for laboratory surveyors, to facilitate the electronic
exchange of laboratory information. The letter included information that will become
part of updated CLIA interpretive guidelines and answers to frequently asked questions.
Longer term next steps will include the HIT Standards Committee recommending standards,
certification criteria, and implementation specifications. ONC and CMS will also
monitor feedback from the Survey and Certification letter and consider possible
regulatory changes if issues cannot be resolved through the ONC standards or CLIA
interpretive guidelines.
|
|
CLIA and EHRs
|
Addenda R and
S
|
Judy Yost, MA, MT (ASCP)
Director, Division of Laboratory Services
Centers for Medicare & Medicaid Services (CMS)
Ms. Yost discussed the implications of EHRs in the context of CLIA regulations.
She related that there are currently several systems for transmitting electronic
health information already in use and issues outside of the CLIA purview, such as
terminology, standardization, and complexity, may create challenges in the future.
The Survey and Certification letter mentioned in the previous presentation is the
predecessor to policy that will be incorporated in the CMS interpretive guidelines
for surveyors and laboratories. She explained the new interpretive guidelines being
written outlines each aspect of the regulations with interpretations and suggestions
for laboratories on how the CLIA requirements can be met. The guidelines will be
available on the CMS website. Ms. Yost listed the specific sections of the CLIA
regulations impacted by EHR, including the preanalytic phase with test ordering
(§493.1105) and test request (§493.1241) as well as the postanalytic phase
with test reporting (§493.1291). She then elaborated on common misperceptions
laboratories have with regard to CLIA regulations and EHRs and provided clarification
for each misperception.
|
|
High-Value Health Care Project: An Initiative of the Quality
Alliance Steering Committee
|
Addendum T
|
Min Gayles Kim, MPH
Engelberg Center for Health Care Reform at Brookings Institution
Scott Endsley, MD, MSc
Co-Chair
Expert Panel on Laboratory Data Integration for Diabetes Care Improvement
Ms. Kim began the presentation with a brief background on the Brookings Institution
Quality Alliance Steering Committee (QASC) which oversees the High-Value Health
Care Activities sponsored by the Robert Wood Johnson Foundation. The QASC includes
stakeholders from all areas of healthcare and has as its goal to provide national
coordination for advancing quality, cost-effective, patient-centered healthcare.
One of the major activities of the High-Value Health Care project is data integration,
which includes an on-going laboratory data integration project related to diabetes.
Ms. Kim noted one of the greatest barriers to coordinating care and improving patient
outcome, as well as measuring provider performance, is the lack of a national health
data infrastructure that can link clinical, administrative, and other electronic
health information at the patient level. She presented the laboratory data integration
project’s phased approach beginning with identifying existing challenges and barriers
followed by prioritizing those barriers and proposing solutions. The barriers identified
and discussed included technical, regulatory, financial, and access barriers.
Dr. Endsley continued the presentation and discussed a number of technical issues
regarding laboratory data integration as well as two CLIA-related issues identified
by the laboratory data integration expert panel. The first CLIA-related issue he
discussed focused on the varying state laws and interpretations of CLIA with respect
to the term “authorized person.” He presented the panel’s recommendation that CMS,
through collaboration with advisory bodies, should update and disseminate the interpretive
guidelines with specific clarification on the definition of “authorized person”
to include other non-ordering providers, EHR, and other Health Insurance Portability
and Accountability Act (HIPAA) covered entities. The second CLIA-related issue he
discussed dealt with the verification by the laboratory of appropriate laboratory
data display in the EHR. The panel recommended that CMS should explicitly describe
the verification process in the absence of electronic verification and said laboratory
data transmitted to an EHR in the endorsed messaging format should be deemed compliant,
provided the EHR system has been certified to display laboratory result data in
compliance with the CLIA requirements. The third CLIA-related issue concerned the
meaningful user requirements. The panel recommended CMS amend the CLIA regulations
to align with these requirements and set a target date for achieving them.
|
|
Electronic Transmission of Laboratory Information and Oversight
of Laboratory Information Systems – CDC Perspective.
|
Addendum U
|
Joan S. Knapp, PhD
Lead subject matter expert: Infectious Diseases Laboratories, Public Health Laboratory
Interoperability Project (PHLIP) Core Vocabulary Team
Centers for Disease Control and Prevention (CDC)
Dr. Knapp presented the PHLIP which actualized the Laboratory Information System
(LIS) that CDC is currently using to receive and transmit data to approximately
fifty state public health laboratories. The first step PHLIP made was to establish
a vocabulary team to work on a common set of agreed upon terms (harmonized vocabulary)
while accommodating multiple terms (exchange of precise terms). She indicated the
number of Logical Observation Identifiers, Names, and Codes (LOINC) available was
limited and not specific enough for PHLIP to use as test codes. She then mentioned
that the Systematized Nomenclature of Medicine – Clinical Terms (SNOMED CT) used
for result codes were also often insufficient for PHLIP’s purposes. Therefore, the
PHLIP team developed its own test and report codes. Dr. Knapp concluded her presentation
by illustrating some challenges the team had encountered and describing lessons
learned and the need for standardized reporting terms.
|
|
FDA Oversight of Laboratory Information Systems
|
Addendum V
|
Alberto Gutierrez, PhD
Director, Office of In-Vitro Diagnostic Device Evaluation and Safety (OIVD)
Center for Devices and Radiological Health
Food and Drug Administration (FDA)
Dr. Gutierrez presented FDA’s classification of and the regulations that apply to
LISs. Under 201(h) of the Federal Food Drug and Cosmetic Act (FDCA). The FDCA considers
an LIS a component part or accessory of a medical device. Under Subpart C – Clinical
Laboratory Instruments, Section 862.2100, an LIS is further classified as a calculator/data
processing module for clinical use and falls under Class 1 (general controls) which
is exempt from pre-market review. Under Class 1, the device must be registered and
the manufacturer must follow good manufacturing practices, report device failures,
have an inventory of tests/software on the market, and have a system for remedying
device failures. Dr. Gutierrez discussed a proposed rule on Medical Device Data
Systems currently in the comment period which discusses software and the electronic
storage, retrieval, transfer, display, and conversion of medical device data. He
then provided a list of guidance documents currently available, including guidance
on communication between software that can be found on the FDA website. He concluded
his presentation with a recommendation that laboratories report to FDA discrepancies
found in laboratory data transmission as a result of software malfunction. Reports
can be submitted anonymously via FDA’s MedWatch (http://www.fda.gov/safety/MedWatch/default.htm).
|
|
Electronic Transmission of Laboratory Information and Oversight
of Laboratory Information Systems
|
Addendum W
|
Anne Delaney, EJD
Sunquest Information Systems, Inc.
Ms. Delaney began her presentation by noting, based on information from their clients,
greater than 75% of laboratory testing is performed by hospitals and the majority
of these results are delivered via paper to the ordering physician. She pointed
out that several variations of HL7 standards are being used by LIS vendors with
LOINC and the latest version of HL7 is rarely being utilized. She then provided
several reasons why providers of laboratory data (e.g., hospitals, laboratories)
are resistant to adopting an LIS, including cost, personnel issues, lack of interoperability
between other LIS products, and non-standard results management and display by ordering
physicians. She concluded her presentation by saying CLIA regulations should be
aligned with new and current practices of EHR, laboratory interfaces should be standardized,
and standards should be implemented to translate test codes.
The CLIAC chair requested the Committee address ten questions in regards to EHR,
Electronic Transmission of Laboratory Information, and CLIA. The questions are provided
below, followed by points made during the discussion.
How can the CLIA requirements be clarified as related to electronic
- Test ordering
- Result reporting
- Sharing of test information
- A member commented that up to 70% of their test requisitions lack specific information
required by CLIA, yet the laboratories are being held responsible for obtaining
this information. Electronic ordering and EHRs could, potentially, help solve this
issue. Ms. Yost responded that CMS understands laboratories cannot meet these requirements
100% of the time, but must do their best to obtain the information from physicians
or other authorized persons who order tests. She agreed simplification of the process
by electronic ordering may be one way to remedy these situations. Ms. Yost went
on to explain that the CMS interpretive guidelines clarify the CLIA regulations
and often include explanations of how the laboratory can meet the requirements.
They follow the order of the regulations for ease of use by both surveyors and laboratories.
She said the new guidelines affecting EHRs, which are currently under review, will
not be prescriptive and do not change the regulations.
Are there mechanisms that could be used to assist in the dissemination of accurate
information pertaining to CLIA and electronic health records?
- A member pointed out how a supervisor’s needs differ from those of a laboratory
technologist’s and requested the interpretive guidelines be subdivided and written
for particular target audiences in order to facilitate dissemination of the material.
Ms. Yost responded that the guidelines are directly tied to specific sections of
the CLIA regulations and are written for all audiences.
In light of advancements in information technology, electronic health records and
laboratory information transfer since CLIA was implemented, are there remaining
gaps that need to be addressed?
- Several members raised concerns about the definition of "authorized person" under
CLIA. A member provided an example of a patient’s cardiologist ordering a laboratory
test and the primary physician needing to re-order the same test in order to view
the results. Another member pointed out that it is not the laboratory’s responsibility
to keep a registry of all patient data, but they are the only ones that have the
information. Mr. Ishee acknowledged this as an issue that is being examined. CLIA
doesn’t necessarily restrict data exchange, he said, but laboratories tend to be
conservative when defining who is considered an authorized person and are inclined
not to provide data to others in order to avoid issues with enforcement later. Ms.
Yost responded that the authorized person should work to facilitate data exchange,
but often competition for patients between doctors as well as unwillingness among
patients to share their data can block this exchange. She noted that state laws
must be followed with regard to health information access.
- A member commented on the disconnect between a laboratory’s responsibility and
their authority regarding decisions pertaining to the electronic exchange of information.
Laboratories cannot tell physicians what system to purchase, yet the responsibility
for verification falls on the laboratory. Another member stated that the laboratory
should establish the gold standard for electronic information exchange. Physicians
want quality results and the cost to both the doctor and patient for missing or
incorrect data is too great. He further offered that physicians could receive a
discount on liability insurance if they chose to use a certified EHR system. Ms.
Yost responded it may be possible to certify EHR vendors thereby assuring appropriate
information is captured and recognized the need to alleviate the laboratory’s responsibility
in the electronic exchange of information. However, the laboratory would still need
to verify that the results reach the authorized person.
Are there other CLIA issues related to information technology and exchange that
should be brought to CLIAC’s attention in the future?
- Numerous examples were related by members that illustrated instances where corruption
of data had taken place during data exchange. In these examples, incorrect data,
missing data, or misinterpreted data resulted after customized viewing screens were
developed for individual physicians. Several members said eliminating customization
and applying standards along with certification of EHR systems would alleviate most
of these issues. The Committee requested a meeting with ONC to discuss this as well
as a follow-up at a future CLIAC meeting.
How can accurate and complete exchange of laboratory information through electronic
channels be assured?
- A member commented that the laboratory must determine who is authorized to receive
results as well as verify correct data transmission. The entire process has become
more complex when the authorized person designates EHRs or others to receive data,
thereby placing greater burden on the laboratory. Ms. Yost responded that the laboratory’s
responsibility ends once the data is received by the authorized person and that
the authorized person is not required to designate an EHR or other individual to
receive data, it is simply an option. Also, an example of how the laboratory can
verify transmission of data would be to have the authorized person print their screen
and send it back to the laboratory.
- Several members agreed LIS vendors should be responsible for assuring accurate
and complete exchange of laboratory information. Dr. Gutierrez replied that software
is regulated as Class 1, which allows the FDA to set special controls or limit requirements
that vendors must meet.
- It was noted by several members that vendors are not familiar with laboratory data
and terminology and the laboratory should be more involved in the development of
LISs and EHRs. Several members of the Committee agreed that standardization among
the vendors is needed, and healthcare should be treated like a business in order
to receive vendor support. An example was given of cell phone standardization where
“3G” has the same meaning for all vendors. Dr. Gutierrez cautioned that if the laboratory
doesn’t become more involved in the decision making process on standards, others
will decide for them.
- One member asked if there was a test bed available that could be used in developing
and testing the certification process for EHRs. Mr. Ishee responded ONC has a test
bed and plans to ensure the appropriate systems are certified although ONC will
probably not be the certification body. He added there is an IFR with specific certification
criteria and a comprehensive NPRM on the certification process is being drafted.
The member responded that the FDA should be responsible for the test bed.
- A Committee member asked how ONC will ensure that international software manufacturers
will meet US standards. Mr. Ishee replied that ONC recognizes and is examining these
issues.
What are the gaps related to electronic information transfer and exchange?
- Several members urged that the issue of having universal patient identifiers be
addressed as soon as possible. Mr. Ishee explained that the federal government will
not be adopting universal patient identifiers and ONC is prohibited by Congress
from spending money on this issue.
- Several members commented on the difficulties of mapping electronic laboratory
data from one system to another. An example was presented of an EHR system that
began installation in 2005 and is currently only halfway completed. There are no
standard laboratory test names or reports from one system to the next, so it takes
a great deal of time and effort to map the data.
- Concerns were raised by several members regarding the use of LOINC (created by
the Regenstrief Institute) as the vocabulary standard in electronic information
exchange. A member proposed that the top 100 laboratories submit their test menus
and use this information to create a standard vocabulary. Another member requested
CDC or the CLSI, with input from all stakeholders, be tasked with putting together
a standard vocabulary for electronic information exchange.
- Several members observed that laboratory data is only part of the data transmittal
issue. The human component of those receiving the data must also be considered.
Laboratories do not always understand the context when results or other information
is received; only the recipients know this information. The members asserted information
exchange needed to move toward intelligent systems and referred to Google and Microsoft
as examples. The EHR should be an enabler of quality, not simply used as a document
system, so that accurate information is presented at the right time.
Are there unique needs for electronic information exchange among laboratories, and
between laboratories and other healthcare providers?
- Mr. Ishee indicated that there is a push for a health information exchange system
where all authorized persons can access data. Currently over 10% of laboratory results
are never reviewed by the ordering physician. One of the biggest issues is that
the paper based system does not allow for meaningful use of information. A member
commented an electronic exchange system would eliminate the laboratory’s responsibility
of sending information to an authorized person. Another member asked if the intent
is to have a single repository or to have regional repositories of health information.
Mr. Ishee clarified that there is no plan for a centralized database. Funding is
provided to the states for infrastructure development; the states decide how the
health information should be handled.
- A member observed that, on some occasions, physicians request access to laboratory
data for research purposes or quality improvement projects that are not subject
to Institutional Review Board approval. However, the laboratory is only permitted
to release data to the authorized person or their designee. The member asked how
would the use of data be regulated or controlled once a repository was created.
Another member replied that patient data exchange in the context of patient care
falls under the HIPAA. Once the data reaches the authorized person, CLIA regulations
no longer apply. Patient notification and consent would then be required for data
sharing.
- A Committee member said the patient should have access to their medical information
and the right to grant access to physicians who care for them. The member elaborated
the reason to have the EHR is to facilitate a doctor’s ability to see the patient’s
history in order to provide the best care. A system similar to those used on social
networking sites, where the patient owns the data and invites others to view it,
was provided as a possible solution. The chair stated the original intent of HIPAA
was to allow the patient access to their medical information; however, HIPAA has
become a significant privacy concern for the medical community.
Who are other stakeholders that need to be part of both short and long term solutions?
- The Committee agreed representation by the laboratory is often absent during the
policy and decision making processes and laboratories should be more involved as
EHR implementation moves forward. The need for the laboratory community to identify
current, on-going efforts and involve themselves in the discussions was recognized.
Mr. Ishee invited the members of CLIAC to attend the next public hearing of ONC
where recommendations will be discussed and to submit official comments to ONC during
the public comment period. He also volunteered to facilitate discussions with members
of CLIAC and the HIT Standards Committee’s Vocabulary Task Force.
- The Committee discussed specific laboratory departments, such as microbiology and
pathology, which often have unique data transmission challenges and requested that
these areas be included in the development and decision making process regarding
EHRs.
Are steps already underway to address the issues?
- A Committee member asked if the use of HL7.2.5.1 will address the issues of physicians
not receiving complete and correct laboratory information. Mr. Ishee answered he
believed it would and elaborated ONC is also focusing on language standardization
using LOINC to establish a base level from which the standard can be further developed.
He added that he believes the American Clinical Laboratory Association (ACLA) is
also working on a standardized compendium of vocabulary.
- Several members discussed the ARRA incentive program established for physicians
who adopt, implement, or use HIT (http://bphc.hrsa.gov/recovery/).
A member noted many doctors will not participate unless there is a penalty or a
law requiring them to do so. Another member commented the incentive is not global
and there are many doctors who are not eligible for the incentive. Mr. Ishee replied
eligibility was decided by Congress and ONC has heard several concerns from those
individuals not considered eligible professionals under the ARRA such as long-term
care providers, chiropractors, dentists, and podiatrists. Also, he said, under the
program there is a monetary penalty for those who are not meaningful EHR users.
- A request for the identification of successful EHR business models was made by
a Committee member. Mr. Ishee responded that ONC is looking at several models including
Kaiser, Medicaid, and those of various states.
Are there additional related items that should be on the CLIAC agenda for a future
meeting?
- A formal recommendation was made to create an EHR workgroup tasked with writing
a work statement that includes specific issues and recommendations for stakeholders
to address. The Committee requested updates regarding the progress of the identified
issues in future meetings.
|
|
PUBLIC COMMENTS
|
ACLA Statement to CLIAC Electronic Transmission of Laboratory Information
|
Addendum Y
|
Department of Veterans’ Affairs Electronic Health Records
|
Addendum Z
|
ADJOURN
Ms. Passiment acknowledged the CDC staff that assembled the meeting agenda and provided
meeting support, and thanked the CLIAC members and partner agencies for their support
and participation.
The following reflects the Committee’s recommendations from this meeting:
- A recommendation was passed stating CLIAC recognizes that there are some rare biochemical
genetic tests which are needed for patient care, but are not currently offered in
CLIA-certified laboratories. CLIAC requests that CMS and the Office of Rare Diseases
Research at NIH identify specific test gaps that exist today and seek support from
the Office of Rare Diseases Research to set up these tests in CLIA-certified laboratories.
This could range from assisting laboratories which currently offer these tests to
obtain CLIA certification to setting up these tests in existing CLIA laboratories.
- A recommendation passed to accept the BGT Workgroup report with accepted changes
as discussed and approved by the Committee.
- A recommendation was made to create an EHR workgroup tasked with writing a work
statement that includes specific issues and recommendations for stakeholders to
address. The Committee requested updates regarding the progress of the identified
issues in future meetings.
Ms. Passiment announced the next CLIAC meeting would be September 1-2, 2010 and
adjourned the Committee meeting.
I certify this summary report of the February 9-10, 2010 meeting of the Clinical
Laboratory Improvement Advisory Committee is an accurate and correct representation
of the meeting.
Elissa Passiment, EdM, CLS(NCA), CLIAC Chair
|
Dated: 05/03/2010
|
|
This page last reviewed: 5/6/2010
|
|